The use of STAT3 blockage in combination with panHER inhibition in cancers including epithelial cancers and sarcoma, with HER-family hyper-activation and resistance to panHER inhibitor, is a new direction to explore and has potential in clinical cancer therapy in the future. The gene discussed is STAT3; the disease is cancer.